Adaptive Biotechnologies Corporation (ADPT): Price and Financial Metrics

Adaptive Biotechnologies Corporation (ADPT)

Today's Latest Price: $47.88 USD

0.19 (0.40%)

Updated Dec 3 10:40am

Add ADPT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

See all "A" rated Strong Buy stocks

ADPT Stock Price Chart Interactive Chart >

Price chart for ADPT

ADPT Price/Volume Stats

Current price $47.88 52-week high $54.20
Prev. close $47.69 52-week low $15.19
Day low $47.05 Volume 60,829
Day high $48.65 Avg. volume 1,065,481
50-day MA $48.82 Dividend yield N/A
200-day MA $39.46 Market Cap 6.55B

Adaptive Biotechnologies Corporation (ADPT) Company Bio

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

ADPT Latest News Stream

Event/Time News Detail
Loading, please wait...

ADPT Latest Social Stream

Loading social stream, please wait...

View Full ADPT Social Stream

Latest ADPT News From Around the Web

Below are the latest news stories about Adaptive Biotechnologies Corp that investors may wish to consider to help them evaluate ADPT as an investment opportunity.

Immunome Aims For $30 Million U.S. IPO

Quick Take Immunome (IMNM) has filed to raise $30 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing antibody therapies for cancer and infectious diseases. IMNM is still at a preclinical stage of development for its programs, so the IPO is...

Donovan Jones on Seeking Alpha | September 27, 2020

Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium

Investment Thesis Adaptive Biotechnologies Corporation (ADPT) has just won its first-ever FDA approval for a blood-based cancer test. However, it's Adaptive’s COVID-19 battle that has attracted investor interest with the share price outperforming the broader market and the leading developers in blood-based cancer tests. The company’s strategy against COVID-19 is...

Dulan Lokuwithana on Seeking Alpha | August 14, 2020

Read More 'ADPT' Stories Here

ADPT Price Returns

1-mo -0.71%
3-mo 33.78%
6-mo 23.63%
1-year 76.22%
3-year N/A
5-year N/A
YTD 60.03%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7226 seconds.